convicted fraudster, Martin Shkreli, made an eyebrow-raising argument to a federal judge Friday, stating that his company Druglike, which he previously described as a "drug discovery software platform," was not engaged in drug discovery. "DefenseIn an affidavit filed Friday, Shkreli described Druglike differently, calling it "professional software for chemists and physicists" that is a "calculator-like tool for scientific researchers to calculate the relative affinity and energetic cost of bonding two molecules. Shkreli was able to get a lawyer in November and the FTC granted Shkreli an extension to December 2 to submit the requested documents and a formal response regarding Druglike